Adverum Biotechnologies to Present at Upcoming Investor Conferences
10 November 2016 - 1:00AM
Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company
committed to discovering and developing novel medicines for
patients suffering from diseases with few or burdensome treatment
options, announced today that Amber Salzman, Ph.D., president and
chief executive officer of Adverum, will present at two upcoming
investor conferences:
- Jefferies 2016 London Healthcare Conference on Wednesday,
November 16, 2016 at 2:40 pm GMT in London
- 28th Annual Piper Jaffray Healthcare Conference on Wednesday,
November 30, 2016 at 4:00 pm ET in New York
The audio portions of the corporate presentation at Jefferies
and the fireside chat at Piper Jaffray will be accessible live
through the investors’ section of the Company’s website at
www.adverum.com. A replay will be available for 14 days following
the presentations.
About Adverum Biotechnologies,
Inc.Adverum is a gene therapy company committed to
discovering and developing novel medicines that can offer
life-changing benefits to patients living with rare diseases or
diseases of the eye who currently have limited or burdensome
treatment options. Adverum has a robust pipeline that includes
product candidates to treat wet AMD, A1AT deficiency, and
hereditary angioedema. Leveraging a next-generation
adeno-associated virus (AAV)-based directed evolution platform, the
Company generates product candidates designed to provide durable
efficacy by inducing sustained expression of a therapeutic protein.
Adverum has collaboration agreements with Regeneron Pharmaceuticals
to research, develop, and commercialize gene therapy products for
ophthalmic diseases and Editas Medicine to explore the delivery of
genome editing medicines for the treatment of inherited retinal
diseases. Adverum has clinical development expertise and core
capabilities in vector optimization, process development,
manufacturing, and assay development. For more information please
visit www.adverum.com.
Contact for Adverum:
Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
jsteier@troutgroup.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2024 to May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From May 2023 to May 2024